Achilles Therapeutics, a biotechnology company focusing on cancer treatment, announced a strategic shift away from its TIL-based cNeT program. This decision led to the discontinuation of ongoing Phase I/IIa clinical trials and a surge in the company’s share price. The company will now focus on collaborations with third parties developing alternative modalities for targeting clonal neoantigens in cancer treatment.